OptimizeRx Corp (OPRX) stock
Close on Nov 17, 2026Market cap $130.72MP/E 28.9Yield –
Earnings
OptimizeRx's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of OptimizeRx's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 4, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 13, 2026after the close | $21.60M | -17.2% | $0.06 | $0.20 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 12, 2026after the close | $20.50M | -29.8% | -$0.04 | $0.16 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026after the close | $19.80M | -9.6% | -$0.03 | $0.14 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 5, 2026after the close | $32.20M | -0.3% | $0.26 | $0.51 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | $26.10M | – | $0.04 | $0.20 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | $29.20M | +55.3% | $0.08 | $0.24 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025after the close | $21.90M | -22.9% | -$0.12 | $0.08 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 12, 2025before the open | $32.30M | – | $0.00 | $0.30 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024after the close | – | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024after the close | $18.80M | +36.2% | -$0.22 | $0.02 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 18, 2024after the close | $28.40M | +118.5% | -$0.23 | $0.26 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 11, 2024after the close | – | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Oct 16, 2023after the close | – | – | – | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023after the close | $13.80M | – | -$0.24 | -$0.01 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023after the close | $13.00M | -5.1% | -$0.37 | -$0.09 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 8, 2023after the close | $19.70M | -3.0% | -$0.02 | $0.25 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022after the close | $15.10M | -6.2% | -$0.19 | $0.07 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022after the close | $13.70M | – | -$0.21 | -$0.01 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 15, 2022after the close | $20.30M | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 10, 2021before the open | $16.10M | – | $0.00 | $0.09 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 27, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 28, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 18, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 13, 2020during market hours | – | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Jul 23, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
OptimizeRx's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| revenueGAAP | FY2026 | $87.00M – $93.00M | – | New | Nov 13, 2026 |
| revenue | FY2026 | $95.00M – $100.00M | $95.00M – $100.00M | Reaffirmed | Aug 12, 2026 |
| adjusted EBITDAnon-GAAP | FY2026 | $21.00M – $25.00M | – | New | Nov 13, 2026 |
| adjusted EBITDAnon-GAAP | FY2026 | $21.00M – $25.00M | $21.00M – $25.00M | Reaffirmed | Aug 12, 2026 |
Guidance vs results
The last range OptimizeRx gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $105.00M – $109.00M | $109.40MΣ4Q | Above range |
| Q1 FY2023 | Revenue | $11.50M – $13.00M | $13.00M | Within range |
Guidance history
Every forecast OptimizeRx put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 13, 2026 | adjusted EBITDA | FY2026 | $21.00M – $25.00M | New |
| Nov 13, 2026 | revenue | FY2026 | $87.00M – $93.00M | New |
| Aug 12, 2026 | adjusted EBITDA | FY2026 | $21.00M – $25.00M | Reaffirmed |
| Aug 12, 2026 | revenue | FY2026 | $95.00M – $100.00M | Reaffirmed |
| May 12, 2026 | adjusted EBITDA | FY2026 | $21.00M – $25.00M | Reaffirmed |
| May 12, 2026 | revenue | FY2026 | $95.00M – $100.00M | Lowered |
| Mar 5, 2026 | Adjusted EBITDA | FY2026 | $21.00M – $25.00M | Raised |
| Mar 5, 2026 | revenue | FY2026 | $109.00M – $114.00M | Lowered |
| Nov 6, 2025 | Adjusted EBITDA | FY2025 | $16.00M – $19.00M | New |
| Nov 6, 2025 | Adjusted EBITDA | FY2026 | $19.00M – $22.00M | New |
| Nov 6, 2025 | revenue | FY2025 | $105.00M – $109.00M | New |
| Nov 6, 2025 | revenue | FY2026 | $118.00M – $124.00M | New |
| Aug 7, 2025 | Adjusted EBITDA | FY2025 | $14.50M – $17.50M | Raised |
| Aug 7, 2025 | revenue | FY2025 | $104.00M – $108.00M | Raised |
| May 12, 2025 | Adjusted EBITDA | FY2025 | $13.00M – $15.00M | Raised |
| May 12, 2025 | revenue | FY2025 | $101.00M – $106.00M | Raised |
| Mar 12, 2025 | Adjusted EBITDA | FY2025 | $12.00M | New |
| Mar 12, 2025 | revenue | FY2025 | $100.00M | New |
| Aug 8, 2024 | Adjusted EBITDA | FY2024 | $11.00M | Reaffirmed |
| Aug 8, 2024 | revenue | FY2024 | $100.00M | New |
| Apr 18, 2024 | Adjusted EBITDA | FY2024 | $11.00M | Reaffirmed |
| Apr 18, 2024 | revenue | FY2024 | $100.00M | Reaffirmed |
| Apr 2, 2024 | Adjusted EBITDA | FY2024 | $11.00M | Reaffirmed |
| Apr 2, 2024 | revenue | FY2024 | $100.00M | Reaffirmed |
| Mar 11, 2024 | adjusted EBITDA | FY2024 | $11.00M | New |
| Mar 11, 2024 | revenue | FY2024 | $100.00M | New |
| Oct 16, 2023 | non-GAAP net income | Q3 FY2023 | $600.00K – $1.00M | New |
| Oct 16, 2023 | revenue | Q3 FY2023 | $15.20M – $15.50M | New |
| Aug 14, 2023 | gross margin rate | FY2023 | 55% – 59% | Lowered |
| Aug 14, 2023 | Revenues | FY2023 | $50.00M – $60.00M | New |
| May 10, 2023 | gross margins | FY2023 | 58% – 62% | Reaffirmed |
| May 10, 2023 | net revenue | FY2023 | +10% | Reaffirmed |
| Mar 8, 2023 | gross margins | FY2023 | 58% – 62% | New |
| Mar 8, 2023 | revenue | Q1 FY2023 | $11.50M – $13.00M | New |
| Mar 8, 2023 | net revenues | FY2023 | +10% | New |
| Nov 8, 2022 | gross margins | FY2022 | 59% – 62% | Raised |
| Nov 8, 2022 | net revenue | FY2022 | $62.00M – $68.00M | Lowered |
| May 4, 2022 | gross margins | FY2022 | 57% – 60% | Reaffirmed |
| May 4, 2022 | net revenues | FY2022 | $80.00M – $85.00M | Reaffirmed |
| Feb 15, 2022 | Gross margins | FY2022 | 57% – 60% | New |
| Feb 15, 2022 | net revenues | FY2022 | $80.00M – $85.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases OptimizeRx filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Update
- Results
- Update
- Results
- Update
- Results
- Update
See a number that looks wrong?